The National Agency for Food and Drug Administration and Control (NAFDAC )has alerted Nigerians to the circulation of a suspected counterfeit toothpaste being sold as the registered ORACARE+ Toothpaste.

The agency, in a public alert issued on August 19, 2026, identified the suspected counterfeit product as ORACIRE+ Toothpaste, warning consumers that its origin, composition, safety and quality had not been verified.

NAFDAC said the alert followed a formal complaint and market intelligence report concerning the widespread distribution of the suspected counterfeit product.

Fake Product Resembles Genuine One

According to the agency, its surveillance team discovered the suspected counterfeit toothpaste at Ojuwoye Market in Mushin, Lagos.

NAFDAC said the product closely resembles the genuine ORACARE+ Toothpaste in its packaging and overall appearance, making it difficult for consumers to distinguish between the two.

The genuine product is manufactured by Aspira Nigeria Limited, while the manufacturer of the suspected counterfeit ORACIRE+ Toothpaste is unknown.

NAFDAC Warns Of Possible Health Risks

NAFDAC warned that counterfeit personal care products may not meet established safety and quality standards and could pose health risks to consumers.

“The origin, composition, safety, and quality of the suspected counterfeit product have not been verified,” the agency stated.

The regulator said it had commenced surveillance activities across the country and directed its zonal directors and state coordinators to investigate the availability and distribution of the suspected counterfeit product.

Consumers Urged To Be Careful

NAFDAC advised consumers, retailers, distributors and healthcare providers to exercise caution when purchasing ORACARE+ Toothpaste.

The agency urged members of the public to buy toothpaste only from reputable and authorised outlets and to carefully examine the product’s packaging and source before making a purchase.

Consumers who come across the suspected counterfeit ORACIRE+ Toothpaste have also been advised to report it to the nearest NAFDAC office or contact the agency through its complaint channels.

NAFDAC further encouraged consumers and healthcare providers to report any adverse effects or suspected side effects associated with regulated products.

The agency said reports could also be made through its Med Safety application or its pharmacovigilance reporting channels.

The alert was listed as Public Alert No. 041/2026, with the content marked as current as of August 20, 2026.